COMPANY
MBQ Pharma
Funding and NIH signals
- SEC Form D raise Raised $991K (Form D filed Aug 14, 2026); +4 other Form D filings in the last 12 months. SEC Form D 0002148840-26-000005 (Aug 14, 2026)
Evidence (5 events)
- Aug 14, 2026 · SEC Form D 0002148840-26-000005
Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 991038; Federal exemptions: 06b - Aug 14, 2026 · SEC Form D 0002148840-26-000004
Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2023-08-24; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 500000; Federal exemptions: 06b - Aug 14, 2026 · SEC Form D 0002148840-26-000003
Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2022-03-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 325000; Total Amount Sold: 325000; Federal exemptions: 06b - Aug 14, 2026 · SEC Form D 0002148840-26-000002
Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2021-02-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 882000; Total Amount Sold: 882000; Federal exemptions: 06b - Aug 14, 2026 · SEC Form D 0002148840-26-000001
Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2018-06-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1530000; Federal exemptions: 06b
- Aug 14, 2026 · SEC Form D 0002148840-26-000005
Timeline
- Trial start Phase 1: A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer source ↗
Upcoming milestones
- Dec 31, 2026 (ESTIMATED) · Phase 1 · A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer · NCT06075810
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06075810 | A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | Phase 1 | Recruiting | Nov 9, 2023 | Dec 31, 2026 (estimated) |